Abstract
Alzheimers disease (AD) represents the most common form of senile dementia and represents a tremendous health problem as the world population is aging. AD is characterized by the accumulation of amyloid β-peptide (Aβ) in the brain and the loss of cholinergic neurons in the basal forebrain. Accumulation of soluble and insoluble assemblies of Aβ in the brain is a crucial event in AD pathogenesis and the presence of amyloid plaques in the brain is required for definitive identification of AD. Yet, there is no correlation between amyloid plaques and the degree of dementia. In the past two decades researchers have devoted their effort to study and explain the mechanisms involved in the pathology of this devastating disease. Studies from different areas of the natural and medical sciences have provided important information towards the elucidation of some of the pathological processes that take place in AD. An aspect of crucial importance is the aggregation state of Aβ peptide and its role in neuropathology. Here, we discuss recent studies aimed at the identification of Aβ protein aggregates, the characterization of their toxic potential and the development of therapeutic strategies that target Aβ aggregation.
Current Protein & Peptide Science
Title: Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide
Volume: 12 Issue: 3
Author(s): Amany Mohamed, Leonardo Cortez and Elena Posse de Chaves
Affiliation:
Abstract: Alzheimers disease (AD) represents the most common form of senile dementia and represents a tremendous health problem as the world population is aging. AD is characterized by the accumulation of amyloid β-peptide (Aβ) in the brain and the loss of cholinergic neurons in the basal forebrain. Accumulation of soluble and insoluble assemblies of Aβ in the brain is a crucial event in AD pathogenesis and the presence of amyloid plaques in the brain is required for definitive identification of AD. Yet, there is no correlation between amyloid plaques and the degree of dementia. In the past two decades researchers have devoted their effort to study and explain the mechanisms involved in the pathology of this devastating disease. Studies from different areas of the natural and medical sciences have provided important information towards the elucidation of some of the pathological processes that take place in AD. An aspect of crucial importance is the aggregation state of Aβ peptide and its role in neuropathology. Here, we discuss recent studies aimed at the identification of Aβ protein aggregates, the characterization of their toxic potential and the development of therapeutic strategies that target Aβ aggregation.
Export Options
About this article
Cite this article as:
Mohamed Amany, Cortez Leonardo and Posse de Chaves Elena, Aggregation State and Neurotoxic Properties of Alzheimer β-Amyloid Peptide, Current Protein & Peptide Science 2011; 12 (3) . https://dx.doi.org/10.2174/138920311795860214
DOI https://dx.doi.org/10.2174/138920311795860214 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin-mediated immune regulation in the development of inflammatory diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design Cerebrovascular Ultrasonography for Selecting Patients for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Emerging Evidence for the Role of Neurotransmitters in the Modulation of T Cell Responses to Cognate Ligands
Central Nervous System Agents in Medicinal Chemistry Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
Current Molecular Medicine Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Early Stage Identification of Alzheimer’s Disease Using a Two-stage Ensemble Classifier
Current Bioinformatics Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Modern Pathology: Protein Mis-Folding and Mis-Processing in Complex Disease
Current Protein & Peptide Science Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Harmaline and its Derivatives Against the Infectious Multi-Drug Resistant Escherichia coli
Medicinal Chemistry The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design BACE Inhibitors as Potential Therapeutics for Alzheimers disease
Recent Patents on CNS Drug Discovery (Discontinued) Dimerization of C-terminal Truncations of α-synuclein and its Effect on the Aggregation Propensity: A Potential of Mean Force Study
Current Chemical Biology Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Desmopressin 30 Years in Clinical Use: A Safety Review
Current Drug Safety The Effect of Acori Graminei Rhizoma and Extract Fractions on Spatial Memory and Hippocampal Neurogenesis in Amyloid Beta 1-42 Injected Mice
CNS & Neurological Disorders - Drug Targets Allosteric Modulation of Muscarinic Acetylcholine Receptors
Current Neuropharmacology Drosophila melanogaster in the Study of Human Neurodegeneration
CNS & Neurological Disorders - Drug Targets